Synairgen Plc (SNG):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Synairgen Plc (SNG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10143
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Synairgen plc (Synairgen) is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-ß/SNG001) for asthma in Phase II trial; and IFN-ß (SNG001) for COPD in Phase I trial. The company develops its drugs based on its BioBank platform technology. Its BioBank comprises blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma and COPD. The company uses these resources to develop in vitro and ex vivo models, which can be used for discovering novel drug targets. It discovers and develops the drug targets through early stages and out-licenses them to other pharmaceutical companies for further development and manufacturing. Synairgen is headquartered at Southampton, the UK.

Synairgen Plc (SNG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Synairgen Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Synairgen Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Synairgen Plc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Pharmaxis Expands Agreement with Synairgen 10
Licensing Agreements 11
AstraZeneca Enters into Licensing Agreement with Synairgen for SNG001 11
Equity Offering 13
Synairgen to Raise USD3.7 Million in Private Placement of Shares 13
Synairgen Raises USD9 Million in Private Placement of Shares 15
Synairgen Announces Private Placement Of Shares For US$2.5 Million 17
Synairgen Completes Private Placement Of Shares For US$4 Million 18
Synairgen Plc – Key Competitors 19
Synairgen Plc – Key Employees 20
Synairgen Plc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Sep 25, 2018: Synairgen: Interim results for the six months ended 30 June 2018 22
Mar 15, 2018: Synairgen: Preliminary statement of results for the year ended 31 December 2017 26
Sep 27, 2017: Synairgen: Interim results for the six months ended 30 June 2017 27
May 17, 2017: Synairgen Announces Preliminary statement of results for the year ended 31 December 2016 28
Product News 29
04/27/2017: Synairgen Provides Update On AZD9412 29
Mar 10, 2017: Synairgen: Additional Positive Data in Lung Fibrosis 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Synairgen Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Synairgen Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Synairgen Plc, Deals By Therapy Area, 2012 to YTD 2018 8
Synairgen Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Pharmaxis Expands Agreement with Synairgen 10
AstraZeneca Enters into Licensing Agreement with Synairgen for SNG001 11
Synairgen to Raise USD3.7 Million in Private Placement of Shares 13
Synairgen Raises USD9 Million in Private Placement of Shares 15
Synairgen Announces Private Placement Of Shares For US$2.5 Million 17
Synairgen Completes Private Placement Of Shares For US$4 Million 18
Synairgen Plc, Key Competitors 19
Synairgen Plc, Key Employees 20
Synairgen Plc, Subsidiaries 21

List of Figures
Synairgen Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Synairgen Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Synairgen Plc (SNG):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Aeterna Zentaris Inc (AEZS):医療機器:M&Aディール及び事業提携情報
    Summary Aeterna Zentaris Inc (Aeterna Zentaris) is a specialty biopharmaceutical company that focuses on the development and commercialization of novel pharmaceutical therapies for the treatment of endocrine disorders. The company’s lead product, macimorelin, a ghrelin receptor agonist and orally-ac …
  • CritiTech Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CritiTech Inc (CritiTech) is a pharmaceutical contract development manufacturing organization that specializes in particle engineering, material characterization, analytical testing, early stage drug development, pre-clinical and clinical manufacturing. The company uses Spray Drying and Supe …
  • Setpoint Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary SetPoint Medical Inc (SetPoint Medical) is a clinical-stage biomedical technology company that develops bioelectronic therapies for the treatment of inflammatory autoimmune diseases. The company develops a new bioelectronic medicine platform, which induces the vagus nerve to activate the bod …
  • U.S. Geothermal Inc. (HTM):企業の財務・戦略的SWOT分析
    U.S. Geothermal Inc. (HTM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Cleco Corporate Holdings, LLC:戦略・SWOT・企業財務分析
    Cleco Corporate Holdings, LLC - Strategy, SWOT and Corporate Finance Report Summary Cleco Corporate Holdings, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Hindustan Construction Co Ltd (HCC):企業の財務・戦略的SWOT分析
    Hindustan Construction Co Ltd (HCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Harrison Catering Services Ltd.:企業の戦略・SWOT・財務情報
    Harrison Catering Services Ltd. - Strategy, SWOT and Corporate Finance Report Summary Harrison Catering Services Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Staidson (Beijing) Biopharmaceuticals Co Ltd (300204)-製薬・医療分野:企業M&A・提携分析
    Summary Staidson (Beijing) Biopharmaceuticals Co Ltd (Staidson) focuses on the research, development and commercialization of biological protein products. The company’s product portfolio comprises Su peptide Health, an injection of mouse nerve growth factor; Shu Taiqing, Shu Wei Xin, Gliclazide, Nab …
  • Cardia Inc:医療機器:M&Aディール及び事業提携情報
    Summary Cardia Inc (Cardia) is a medical device company that designs, manufactures and markets transcatheter septal occluders for cardiac defect patients. The company offers products such as ultrasept ASD occluder, ultrasept LAA occluder, ultrasept PFO occluder, fontan occluder, ultrasept cribriform …
  • Interconexion Electrica SA ESP (ISA):企業の財務・戦略的SWOT分析
    Interconexion Electrica SA ESP (ISA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Ricoh India Ltd:企業の戦略的SWOT分析
    Ricoh India Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Choppies Enterprises Limited (CHOPPIES):企業の財務・戦略的SWOT分析
    Choppies Enterprises Limited (CHOPPIES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • NBN Co Ltd:企業の戦略的SWOT分析
    NBN Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • China Shipbuilding Industry Corporation:戦略・SWOT・企業財務分析
    China Shipbuilding Industry Corporation - Strategy, SWOT and Corporate Finance Report Summary China Shipbuilding Industry Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Precision System Science Co Ltd (7707):医療機器:M&Aディール及び事業提携情報
    Summary Precision System Science Co Ltd (PSS) is a medical device company that develops, manufactures and sells automated systems, physicochemical instruments, software, and others. The company provide products such as automated nucleic acid isolation system, large sample volume nucleic acid extract …
  • Precision System Science Co Ltd (7707)-医療機器分野:企業M&A・提携分析
    Summary Precision System Science Co Ltd (PSS) is a medical device company that develops, manufactures and sells automated systems, physicochemical instruments, software, and others. The company’s products include automated nucleic acid isolation system, large sample volume nucleic acid extraction sy …
  • American Shared Hospital Services (AMS)-医療機器分野:企業M&A・提携分析
    Summary American Shared Hospital Services (ASHS) is a healthcare company that offers medical equipment to hospitals and medical centers. The company offers financial and healthcare tech solutions. Its financing solutions comprise feasibility studies and reimbursement analysis, facilities planning an …
  • Export Development Canada-エネルギー分野:企業M&A・提携分析
    Summary Export Development Canada (EDC) is an export credit agency that provides financial services. The agency supports and promotes Canada’s export trade by providing finance and insurance solutions to companies with export contracts. It provides guarantees to banks to provide their exporting cust …
  • Edinburgh Molecular Imaging Ltd:企業の製品パイプライン分析2018
    Summary Edinburgh Molecular Imaging Ltd (EM Imaging) is a biotechnology company that develops optical molecular imaging technology. The company offers discovery and development of small molecules and peptides. It designs agents to improve the diagnosis and treatment of cancer and lung diseases. EM I …
  • Dechra Pharmaceuticals Plc (DPH):企業の財務・戦略的SWOT分析
    Summary Dechra Pharmaceuticals Plc (Dechra) is a manufacturer and distributor of veterinary pharmaceutical products. The company's product portfolio includes vetoryl, felimazole, thyforon, malaseb, canaural, isaderm, cardisure, comfortan, soludox, methoxasol, cyclospray and octacillin, among others. …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆